Nutra Pharma Corporation (NPHC) Targeting Underser
Post# of 102
Posted On: 12/18/2015 3:55:35 PM
Nutra Pharma Corporation (NPHC) Targeting Underserved Pharmaceutical Indications with Proprietary Therapeutic Protein Products
Nutra Pharma Corporation (OTC: NPHC) is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The company’s product portfolio includes Cobroxin, the first over-the-counter pain reliever clinically proven to treat moderate to severe chronic pain, and Nyloxin, the only non-narcotic and non-addictive treatment for severe pain. Both products were developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm.
Currently, ReceptoPharm is developing proprietary therapeutic protein products for the prevention and treatment of viral and neurological diseases by leveraging the specialized receptor-binding proteins found in nature, particularly those found in cobra venom. The company’s leading drug candidates, RPI-MN and RPI-78M, are being developed for the treatment of HIV and multiple sclerosis, respectively. By leveraging a proprietary chemical process, ReceptoPharm is able to create drugs that possess a host of desirable properties – including lack of toxicity (which eliminates the threat of overdosing), extended shelf life and total absence of serious adverse side effects.
Earlier this month, Nutra Pharma took a significant step in the development of RPI-78M when it announced that it had applied for an orphan drug designation from the U.S. Food and Drug Administration for the treatment of Myasthenia Gravis (MG). If received, this would be the company’s second orphan drug designation approved in recent weeks. In September, Nutra Pharma was granted the designation for the treatment of Pediatric Multiple Sclerosis (MS).
Orphan drug designations are designed to encourage the development of drugs which may provide significant benefits to patients suffering from rare diseases. For pharmaceutical companies, the program offers a seven-year period of market exclusivity, as well as tax credits and, in many cases, grant funding to cover a portion of clinical research costs.
“We have been clear over the last year that we would be moving our drug platforms forward,” Rik J. Deitsch, chairman and chief executive officer of Nutra Pharma, stated in a news release. “This includes our work in Pediatric Multiple Sclerosis as well as additional potential orphan designations for our therapeutic pipeline.”
Although MS most commonly occurs in adults, it also effects an estimated 10,000 children in the U.S., according to the National Multiple Sclerosis Society. There are currently no approved treatments for pediatric MS. Instead, FDA-approved self-injectable disease-modifying therapies developed for use in adults are often used ‘off-label’ in children. Large clinical trials are still needed to assess the treatment efficacy of these therapies in the pediatric population, making a therapeutic designed and tested specifically to treat pediatric MS a potential game changer moving forward.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Nutra Pharma Corporation (OTC: NPHC) is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The company’s product portfolio includes Cobroxin, the first over-the-counter pain reliever clinically proven to treat moderate to severe chronic pain, and Nyloxin, the only non-narcotic and non-addictive treatment for severe pain. Both products were developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm.
Currently, ReceptoPharm is developing proprietary therapeutic protein products for the prevention and treatment of viral and neurological diseases by leveraging the specialized receptor-binding proteins found in nature, particularly those found in cobra venom. The company’s leading drug candidates, RPI-MN and RPI-78M, are being developed for the treatment of HIV and multiple sclerosis, respectively. By leveraging a proprietary chemical process, ReceptoPharm is able to create drugs that possess a host of desirable properties – including lack of toxicity (which eliminates the threat of overdosing), extended shelf life and total absence of serious adverse side effects.
Earlier this month, Nutra Pharma took a significant step in the development of RPI-78M when it announced that it had applied for an orphan drug designation from the U.S. Food and Drug Administration for the treatment of Myasthenia Gravis (MG). If received, this would be the company’s second orphan drug designation approved in recent weeks. In September, Nutra Pharma was granted the designation for the treatment of Pediatric Multiple Sclerosis (MS).
Orphan drug designations are designed to encourage the development of drugs which may provide significant benefits to patients suffering from rare diseases. For pharmaceutical companies, the program offers a seven-year period of market exclusivity, as well as tax credits and, in many cases, grant funding to cover a portion of clinical research costs.
“We have been clear over the last year that we would be moving our drug platforms forward,” Rik J. Deitsch, chairman and chief executive officer of Nutra Pharma, stated in a news release. “This includes our work in Pediatric Multiple Sclerosis as well as additional potential orphan designations for our therapeutic pipeline.”
Although MS most commonly occurs in adults, it also effects an estimated 10,000 children in the U.S., according to the National Multiple Sclerosis Society. There are currently no approved treatments for pediatric MS. Instead, FDA-approved self-injectable disease-modifying therapies developed for use in adults are often used ‘off-label’ in children. Large clinical trials are still needed to assess the treatment efficacy of these therapies in the pediatric population, making a therapeutic designed and tested specifically to treat pediatric MS a potential game changer moving forward.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)